New Xylem buyback plan and what it could mean for shareholders
Xylem (XYL) has authorized a new share repurchase program of up to US$1.5b with no expiration date, prompting fresh questions about how this move might affect valuation, capital allocation, and long term shareholder returns.
See our latest analysis for Xylem.
The new buyback comes at a time when Xylem’s share price has eased, with a 30 day share price return of an 8.93% decline and a year to date share price return of a 7.96% decline. Meanwhile, the 3 year total shareholder return of 30.20% points to longer term gains and suggests that momentum has cooled recently.
If this kind of capital return story has your attention, it could be worth broadening your search and checking out our screener of 24 power grid technology and infrastructure stocks as another way to find infrastructure names tied to long term utility investment themes.
With the shares pulling back recently but trading at what some models suggest is roughly a 20% intrinsic discount, the key question is whether Xylem is genuinely mispriced today or if the market is already assuming plenty of future growth.
Most Popular Narrative: 20.3% Undervalued
With Xylem last closing at $126.19 versus a narrative fair value of $158.41, the current price sits well below what this widely followed model suggests, raising clear questions about whether the market is fully reflecting the long term earnings and cash flow story.
Significant and increasing investment in aging water infrastructure (notably in the U.S. and U.K.) underpins a strong multi-year backlog (> $5 billion), with anticipated order rebounds as funding cycles and regulatory timelines normalize, supporting steady revenue growth and greater earnings visibility.
Curious what earnings path and margin profile sit behind that fair value gap? The narrative leans on measured growth, richer profitability, and a premium future earnings multiple. The specific mix of assumptions might surprise you.
Result: Fair Value of $158.41 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on funding and execution, with delays in government-backed water projects or hiccups integrating Evoqua, both of which have the potential to challenge that upbeat earnings path.
Find out about the key risks to this Xylem narrative.
Next Steps
If that mix of caution and optimism feels familiar, it is a good time to review the numbers yourself and decide quickly where you stand, including weighing up 4 key rewards.
Ready to hunt for more investment ideas?
If this has sharpened your thinking on Xylem, do not stop here, use the Simply Wall Street Screener to uncover more possibilities that fit your style.
- Target potential mispricings by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices the market may not fully recognize yet.
- Prioritise resilience by focusing on 73 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
- Get ahead of the crowd by reviewing our screener containing 24 high quality undiscovered gems that have strong fundamentals but limited attention so far.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com